Earnings ·
Arbutus Biopharma reported a net loss of $5.1 million for Q2 2026, or $0.03 per share, compared to a net income of…
ABUSArbutus Biopharma Corp
Arbutus Biopharma reported a net loss of $5.1 million for Q2 2026, or $0.03 per share, compared to a net income of $2.5 million in the prior year period. Revenue declined to $1.0 million from $10.7 million due to the conclusion of a strategic partnership with Qilu. The company holds $92.6 million in cash and equivalents as of June 30, 2026. In July 2026, Arbutus received its share of approximately $178.4 million from a $950 million settlement with Moderna regarding patent infringement litigation. The company announced plans to return up to $230 million in capital to shareholders starting in Q3 2026 through potential share repurchases or tender offers. Additionally, Arbutus filed international lawsuits against Pfizer and BioNTech over lipid nanoparticle technology and received FDA Fast Track designation for its hepatitis B candidate imdusiran. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases.